It quickly became clear that VolparaAnalytics would be invaluable based on its ability to help us better understand our patient population and support density-based supplemental imaging,” said Michael J. Masone.
CHICAGO (PRWEB) November 24, 2014
Volpara Solutions announced today that it will launch VolparaAnalytics version 1.2 at the 100th Annual Meeting of the Radiology Society of North America (RSNA), November 30-December 5, 2014 (RSNA Booth 1752 – South Hall). Volpara Solutions will showcase the latest version of VolparaAnalytics and the rest of its innovative suite of quantitative breast imaging tools, including VolparaDensity and VolparaDoseRT, which enable personalized measurements of volumetric density, patient-specific dose, breast compression and other factors designed to provide critical insight for breast imaging quality and workflow.
VolparaAnalytics, a centralized dashboard which presents key mammography metrics, works by automatically collating data from digital mammography and tomosynthesis units to enable cross-comparison of patient populations, mammography systems and operator performance. VolparaAnalytics is in use supporting quality assurance at breast imaging centers around the globe by monitoring critical elements of the breast imaging process and generating key metrics to help breast imaging centers identify and address potential issues early.
The new version of VolparaAnalytics, which will be available in early 2015, features an enhanced user interface and reporting tools, and delivers expanded breast imaging metrics to users including additional quality metrics, new temporal analysis tools, additional tools to analyse patient positioning and patient-dose, and time between study acquisitions.
“We initially adopted Volpara to standardize breast density assessment across the practice, but it quickly became clear that VolparaAnalytics would be invaluable based on its ability to help us better understand our patient population and support density-based supplemental imaging,” said Michael J. Masone R.T. (R)(M)(MR)(S), R.D.M.S., Director, Capital Imaging Associates. “With high breast density impacting more than 40 percent of women, there is some concern about over utilization of ultrasound or other supplemental imaging. VolparaAnalytics gives us objective data to show referring physicians and payors the percentage of patients we call dense and know that we have consistent, reproducible results.”
Volpara Solutions was recently recognized with the 2014 Technology Innovation Leadership Award in Breast Imaging from Frost & Sullivan based on independent analysis of the company’s technology excellence and visionary innovation. According to Frost & Sullivan, “We laud Volpara Solutions’ continuous leadership in technology innovation, thoughtfulness in identifying the unmet need for dose tracking in breast imaging, and a clear vision for what analytics can achieve in the early detection and treatment of breast cancer.”
“One key new feature of the latest version of VolparaAnalytics is temporal analysis reporting, which allows users to view key breast imaging metrics such as compression force, applied pressure, and mean glandular dose results over time to quickly identify inconsistencies that might have developed,” said Ralph Highnam, PhD., Volpara Solutions CEO and Chief Scientist. “By providing objective volumetric context, this provides actionable insight to help breast centers improve patient care and productivity.”
VolparaAnalytics runs on top of VolparaDensity, a unique software tool in use at breast imaging centers worldwide to help radiologists objectively assess density from both digital mammography and tomosynthesis images and to determine which women would benefit from additional screening. Highly correlated to breast MR assessments, VolparaDensity is a reliable tool that automatically generates an objective measurement of volumetric breast density correlated to the ACR (American College of Radiology) breast density categories. To date, more than 4-million women have had their breast density analyzed using VolparaDensity. VolparaDoseRT provides a standardized measurement of patient-specific dose with consistent dose results across mammography systems from different manufacturers.
About Volpara Solutions
Founded with the goal of helping radiologists give women the most accurate information possible regarding their breast health, Volpara Solutions is the wholly owned sales and marketing arm of Matakina Technology Limited of New Zealand. Cleared by the FDA, HealthCanada, the TGA, and CE-marked, VolparaDensity provides an objective volumetric measure of breast density from both digital mammography and tomosynthesis images. VolparaDensity is part of a suite of quantitative breast imaging tools built on the Volpara Solutions algorithm that allows for personalized measurements of density, patient-specific x-ray dose, breast compression and other factors designed to provide critical insight for breast imaging workflow. For more information, visit http://www.volparasolutions.com
Chris K. Joseph